Bavituximab - redOrbit

News - Bavituximab

Peregrine Pharmaceuticals Reports Data From Newly Published Research Reinforcing Potential of Targeting PS in HIV Infection

2010-04-05 08:00:00

TUSTIN, Calif., April 5 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced the publication of data showing phosphatidylserine (PS)-targeting antibodies can block one of the key ways the AIDS virus gains entry into certain blood cells.

Peregrine Announces Data From Four Studies to be Presented at American Association for Cancer Research Annual Meeting

2010-03-31 08:00:00

TUSTIN, Calif., March 31 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.

New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model

2009-11-10 08:30:00

TUSTIN, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer

2009-10-21 08:30:00

TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today reported positive results from its Phase II trial evaluating bavituximab in combination with docetaxel in patients with advanced breast cancer.

NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers

2009-08-26 07:00:00

TUSTIN, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S.

More News (43 articles) »

News - Bavituximab

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health